Akebia Therapeutics, Inc.AKBANASDAQ
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+55.5%
5Y CAGR+35.7%
Studio
Year-over-Year Change

Year-over-year free cash flow growth rate

3Y CAGR
+55.5%/yr
Annual compound
5Y CAGR
+35.7%/yr
Recent acceleration
Percentile
P100
Near historical high
vs 5Y Ago
4.6x
Strong expansion
Streak
1 yr
Consecutive growthAccelerating
PeriodValue
2025267.09%
2024-74.02%
202368.08%
202271.04%
2021-128.56%
202058.08%
2019-166.49%
2018-71.51%
2017-204.59%
2016204.59%